One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Lantern Pharma Inc.
LTRN · NCM · Healthcare · Biotechnology
Current price
$0.66
52-week range
$0.60 - $4.34
Market cap
$9.86M
Balance sheet
Healthy
-41.05x Concerning
Net cash $7.32M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Lantern Pharma Inc.
Lantern Pharma is a drug company trying to find new cancer medicines, mainly for lung cancer and brain tumors, and they are working on these in India. Their main income will eventually come from selling these drugs if they get approved, which is important because it means they could help patients and make money.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-5.59M
FY2024 Q4
$-3.97M
FY2025 Q1
$-4.38M
FY2025 Q2
$-3.94M
FY2025 Q3
$-4.57M
FY2025 Q4
$-2.79M
Revenue
—
Net income
$-7.07M
Diluted EPS
-0.57
Operating cash flow
$-2.94M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-3.33M
Diluted EPS
-0.30
Operating cash flow
$-3.77M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-4.07M
Diluted EPS
-0.36
Operating cash flow
$-2.79M
Free cash flow
$-2.79M
Fetching…
Sources
Revenue
—
Net income
$-4.18M
Diluted EPS
-0.39
Operating cash flow
$-4.57M
Free cash flow
$-4.57M
Fetching…
Sources
Revenue
—
Net income
$-4.33M
Diluted EPS
-0.40
Operating cash flow
$-3.94M
Free cash flow
$-3.94M
Fetching…
Sources
Revenue
—
Net income
$-4.54M
Diluted EPS
-0.42
Operating cash flow
$-4.38M
Free cash flow
$-4.38M
Fetching…
Sources
Revenue
—
Net income
$-5.88M
Diluted EPS
-0.54
Operating cash flow
$-3.97M
Free cash flow
$-3.97M
Fetching…
Sources
Revenue
—
Net income
$-4.51M
Diluted EPS
-0.42
Operating cash flow
$-5.58M
Free cash flow
$-5.59M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.66
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $7.3M - more cash than debt. Interest coverage -41.1x.
Net debt
$-7.32M
Interest coverage
-41.05x
Lantern Pharma Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
LTRN
BASELINE
Lantern Pharma Inc.
Total debt $39.72K Interest coverage -41.05x This is the baseline the peer rows are being compared against.
Total debt $0.00 Interest coverage -1,110.88x Neither company has much profit cushion over interest right now.
Total debt $5.05M Interest coverage -15.67x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -64,373.46x Neither company has much profit cushion over interest right now.
What you should know
The case for and against LTRN
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -400.9% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.33x
P/B
-2.62x
P/S
—
EV/EBITDA
-0.09x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-400.9%
ROA
-74.3%
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
1.96x
Quick ratio
1.71x
Total debt
$39.72K
Total cash
$7.36M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-1.63
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-14.08M
Free CF TTM
$-15.68M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—